Biopharma companies make big bets and investments in every single drug candidate that enters the drug development process. Yet, making difficult strategic decisions on which trials to pursue, how to design trials (e.g. head-to-head; which drug candidate; non-inferiority or superiority; which primary and secondary endpoints; which bio-markers; which types of patients), and how to increase the overall probability of success, hasn’t changed in many years.  Recently, companies are moving toward investing more heavily in clinical and real world data and bringing in AI solutions in order to have new tools to help make these important decisions.

Join the GNS team for our latest webinar where Nelia Padilla, SVP of Precision Medicine, and Kathleen Tarnowski, Sales Director & Business Development, will share how GNS has leveraged its unique AI technology to help biopharma partners more efficiently identify patients for trial enrollment and utilized diverse data assets to improve clinical trial efficiency.

In this 30 minute webinar, we cover:

  1. How using AI can ease patient identification and recruitment for trials
  2. How we can design better trial protocols to speed time to market and avoid amendments
  3. How to leverage existing data investments, including real-world data, to achieve next level insights and decisions

View content.